Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.
about
Can mammalian cloning combined with embryonic stem cell technologies be used to treat human diseases?Biography of Rudolf JaenischNuclear reprogramming and stem cell creationDisease-specific induced pluripotent stem cellsTherapeutic cloning: promises and issuesScientists and bioethics councilsCharacterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sitesPhage integrases for the construction and manipulation of transgenic mammalsHuman iPSC for Therapeutic Approaches to the Nervous System: Present and Future ApplicationsPluripotent stem cells in research and treatment of hemoglobinopathiesHematopoietic stem cell engineering at a crossroadsOptimizing the design of oligonucleotides for homology directed gene targeting.A robust strategy for negative selection of Cre-loxP recombination-based excision of transgenes in induced pluripotent stem cellsTechniques of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell DerivationStem cells, the molecular circuitry of pluripotency and nuclear reprogrammingNeurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's diseaseRegeneration of Hair Cells: Making Sense of All the Noise.Survival of partially differentiated mouse embryonic stem cells in the scala media of the guinea pig cochlea.Characterization of spermatogonial stem cells lacking intercellular bridges and genetic replacement of a mutation in spermatogonial stem cells.A look to future directions in gene therapy research for monogenic diseases.Progress toward the clinical application of patient-specific pluripotent stem cellsSomatic cell dedifferentiation/reprogramming for regenerative medicineIdentification of inappropriately reprogrammed genes by large-scale transcriptome analysis of individual cloned mouse blastocystsFunctional evaluation of ES-somatic cell hybrids in vitro and in vivo.Propagation of an infertile hermaphrodite mouse lacking germ cells by using nuclear transfer and embryonic stem cell technologyWhat to call human cloning: the technical terminology increasingly used in the cloning debate sidesteps the ethical questions raisedInterspecies somatic cell nuclear transfer is dependent on compatible mitochondrial DNA and reprogramming factorsHOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells.Differentiation of neuron-like cells from mouse parthenogenetic embryonic stem cells.Autologous blood cell therapies from pluripotent stem cells.Chromatin protein L3MBTL1 is dispensable for development and tumor suppression in mice.Cure of ADPKD by selection for spontaneous genetic repair events in Pkd1-mutated iPS cellsHarnessing the potential of induced pluripotent stem cells for regenerative medicine.Embryonic stem cell-derived hematopoietic stem cells.Unique differentiation profile of mouse embryonic stem cells in rotary and stirred tank bioreactors.Correction of the sickle cell mutation in embryonic stem cellsES cells derived from cloned and fertilized blastocysts are transcriptionally and functionally indistinguishable.Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus.Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells.Survival of skin graft between transgenic cloned dogs and non-transgenic cloned dogs.
P2860
Q24544165-AAF80CE4-0009-464E-934D-59E4DD246DB0Q24564136-7B5FBA23-AA75-4EF0-931A-1FD9D6166211Q24620354-38DDC041-70B8-48DF-BC6E-224CC5048F2FQ24641981-09A4D26D-6485-4D8D-BBC1-6221D5B091AFQ24645082-BA28B8FB-4170-4044-8A4D-3392AF1CC61AQ24793485-2336E1E0-A8D4-40BF-B6EB-A0F5A6BC78F1Q24794781-B62F0B7D-393F-43C5-883A-A4BD24E2586CQ24798494-EFDE88C0-A0F2-49CB-BBA7-B17D5DB39D19Q26772309-7E755538-74F5-4F52-B950-33428A4FF586Q26825713-200250B0-23AF-4E70-9FD4-EDC9ED14D940Q27001570-DA8C45D7-79F6-46BD-AFAD-7D12F77021CFQ27313801-9B5DA9D5-77A0-4B4A-A80F-34ADD15BE5BDQ27318778-E3608F4E-89C0-4F59-AC0F-4A6523145590Q28066087-808C9F54-92FA-4342-A49A-E13C8E8BACD9Q29614416-7BA9D65F-B17C-45B5-8D30-64C6C49A34A3Q29619506-BA09B11F-04E0-4CD3-9D94-17ADDE2FCE1AQ30467210-42E8AC8E-E896-44E1-91C2-ADBE0AFB9F32Q30492590-890D9F7B-D3F4-496A-83CD-F52D662F2CC4Q31068431-40190B73-F73D-4AF9-92BA-EE334696F417Q33258821-B9465287-EAC4-489E-BC3B-3AB9C6BDE2A1Q33559694-EACB11B8-7051-46A1-99F5-A2DDC1A772CFQ33614812-836B41B2-D08D-4EF6-93A2-A876DDD54236Q33627711-C66DD993-AD25-44AC-AC15-B69E16477B20Q33648749-7CFB48F6-B90F-4F77-A519-CABCBBA212ABQ33715878-EDAEC480-A0C9-4F69-8B3C-8C4D1FE6171DQ33757961-0BA04416-BD12-43B0-9986-90440E0CCE27Q33893736-3E1EB76E-4DAB-453B-B717-A7D490EE500DQ33922993-6F50A79C-E21A-45DD-A243-2A7EFD8371D5Q33936482-0FC0013A-ABB0-4150-BF73-D30E1D24CCBDQ34034385-1EE5A02A-BA7C-43A8-A299-9558B28425F2Q34107271-A90FF852-0EA3-41A6-A034-FFA77A15455EQ34162972-AD93FEB0-1182-45F9-96C5-06F51D792D25Q34182222-93E6F365-1055-4EB5-968B-BF503A11EACDQ34244938-F4DAEFD4-B206-4E92-B765-89DC714FCCCEQ34246498-B99D37C3-D431-4247-9ED1-55A2116E814BQ34249583-B80B2858-C989-4555-9183-FB65AE560614Q34304912-F54C0BAF-B27B-434B-AE49-B356CBC139E3Q34398115-92EBF175-3CB3-4F66-91B8-C4E2B4FCDD38Q34417577-85DFDB7D-9157-4FE4-9CCD-FD390C86397CQ34455887-E5A2ABCF-FC7B-4536-9272-1D9E38D15FE4
P2860
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Correction of a genetic defect ...... ombined cell and gene therapy.
@en
type
label
Correction of a genetic defect ...... ombined cell and gene therapy.
@en
altLabel
Correction of a genetic defect ...... combined cell and gene therapy
@en
prefLabel
Correction of a genetic defect ...... ombined cell and gene therapy.
@en
P50
P1433
P1476
Correction of a genetic defect ...... ombined cell and gene therapy.
@en
P2093
William M Rideout
P356
10.1016/S0092-8674(02)00681-5
P407
P577
2002-04-01T00:00:00Z